Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Highlights Hands-On Approach To China Inspections In Budget Plan

This article was originally published in PharmAsia News

Executive Summary

The inspection focus of U.S. FDA’s budget request is largely on adding more personnel, but the agency continues to think about how best to target and leverage its resources in its globalization plan.

You may also be interested in...



FDA's Projected $20 Mil. In 2013 Biosimilar User Fees Translates Into 68 More Staffers

Administration’s proposed fiscal year 2013 spending plan includes $4.5 billion for FDA, with $2 billion or 44% provided by various user fees.

Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed

At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.

Foreign Regulator Exchange Program Contemplated By U.S. State Department

FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel